<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03712943</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-19581</org_study_id>
    <nct_id>NCT03712943</nct_id>
  </id_info>
  <brief_title>Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer</brief_title>
  <official_title>Phase I Study of Regorafenib and Nivolumab in Mismatch Repair (MMR) Proficient Advanced Refractory Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to test the safety, tolerable side effects, and determine&#xD;
      the highest tolerable dose of the combination of Regorafenib and Nivolumab. Researchers want&#xD;
      to find out if this combination of Regorafenib and Nivolumab can help people with metastatic&#xD;
      colorectal cancer with mismatch repair (MMR) proficiency.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 23, 2018</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Actual">September 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Regorafenib and Nivolumab</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>To determine the maximum tolerated dose of Regorafenib in combination with Nivolumab in advanced, refractory colorectal cancers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>Every 2nd cycle (Cycles are 28 days) up to 12 months</time_frame>
    <description>To access response rate using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 24 months after conclusion of treatment</time_frame>
    <description>Occurrence of Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and Severity of Adverse Events</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>To evaluate the frequency and severity of adverse events and tolerability of the combination regimen.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Metastatic Colorectal Cancer</condition>
  <condition>Colon Cancer</condition>
  <arm_group>
    <arm_group_label>Regorafenib and Nivolumab Combination - Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation: To find the dose of regorafenib that can be safely given with nivolumab in patients with advanced, refractory colorectal cancers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regorafenib and Nivolumab Combination - Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Expansion: To find the effect on tumor of the combination of regorafenib and nivolumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib</intervention_name>
    <description>Regorafenib orally 80 mg daily for 21 days (3 weeks on, 1 week off).</description>
    <arm_group_label>Regorafenib and Nivolumab Combination - Escalation</arm_group_label>
    <arm_group_label>Regorafenib and Nivolumab Combination - Expansion</arm_group_label>
    <other_name>Stivarga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab 240 mg administered intravenously every 2 weeks.</description>
    <arm_group_label>Regorafenib and Nivolumab Combination - Escalation</arm_group_label>
    <arm_group_label>Regorafenib and Nivolumab Combination - Expansion</arm_group_label>
    <other_name>OPDIVO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of colorectal adenocarcinoma&#xD;
&#xD;
          -  Proficient DNA mismatch repair (MMR) or stable microsatellite disease.&#xD;
&#xD;
          -  Participants with the presence of at least one lesion with measurable disease as&#xD;
             defined by 10mm in longest diameter for a soft tissue lesions or 15mm in short axis&#xD;
             for a lymph node by RECIST 1.1 for response assessment.&#xD;
&#xD;
          -  Participants must have received and progressed through or become intolerant to&#xD;
             fluoropyrimidine, irinotecan, oxaliplatin, and bevacizumab, and if K-ras wild type,&#xD;
             cetuximab or panitumumab containing therapies. Exceptions may apply.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Score 0 or 1&#xD;
&#xD;
          -  Estimated life expectancy over 3 months.&#xD;
&#xD;
          -  Adequate bone marrow, liver and renal function.&#xD;
&#xD;
          -  Participants must not have had chemotherapy, major surgery, monoclonal antibody&#xD;
             therapy or experimental therapy within the 21 days prior to the start of regorafenib&#xD;
             and nivolumab administration&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum or urine pregnancy test&#xD;
             (minimum sensitivity 25 IU/L or equivalent units of HCG) performed within 24 hours&#xD;
             prior to the start of study drug and then every 4 weeks. Post-menopausal women&#xD;
             (defined as no menses for at least 1 year) and surgically sterilized women are not&#xD;
             required to undergo a pregnancy test.&#xD;
&#xD;
          -  Participants (men and women) of childbearing potential must agree to use adequate&#xD;
             contraception beginning at the signing of the Informed Consent Form (ICF) until at&#xD;
             least 5 months for females and 7 months for males after the last dose of study drug&#xD;
&#xD;
          -  Participants must be able to understand and be willing to sign the written informed&#xD;
             consent form and be willing and able to comply with scheduled visits, treatment&#xD;
             schedule, laboratory testing, and other study requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with active Central Nervous System (CNS) metastases If CNS metastases are&#xD;
             treated and participants are at neurologic baseline for at least 2 weeks prior to&#xD;
             enrollment, they will be eligible but will need a Brain MRI prior to enrollment.&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic pressure &gt;140 mm Hg or diastolic pressure &gt; 90 mm&#xD;
             Hg [NCI-CTCAE v5.0] on repeated measurement) despite optimal medical management.&#xD;
&#xD;
          -  Active or clinically significant cardiac disease.&#xD;
&#xD;
          -  Women who are pregnant or breast-feeding&#xD;
&#xD;
          -  Prior therapy with regorafenib, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or&#xD;
             anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically&#xD;
             targeting T-cell costimulation or checkpoint pathways).&#xD;
&#xD;
          -  Previous or concurrent cancer within 3 years prior to treatment start EXCEPT for&#xD;
             curatively treated cervical cancer in situ, non-melanoma skin cancer, superficial&#xD;
             bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor invades&#xD;
             lamina propria)].&#xD;
&#xD;
          -  Active autoimmune disease that has required systemic treatment in the past 2 years.&#xD;
             Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid&#xD;
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a&#xD;
             form of systemic treatment.&#xD;
&#xD;
          -  Ascites, pleural effusion, or pericardial fluid requiring drainage in the last 4 weeks&#xD;
&#xD;
          -  Participants with phaeochromocytoma&#xD;
&#xD;
          -  Ongoing infection &gt; Grade 2&#xD;
&#xD;
          -  Presence of a non-healing wound, or bone fracture.&#xD;
&#xD;
          -  Renal failure requiring hemo-or peritoneal dialysis.&#xD;
&#xD;
          -  Seizure disorder requiring medication.&#xD;
&#xD;
          -  Interstitial lung disease with ongoing signs and symptoms at the time of informed&#xD;
             consent.&#xD;
&#xD;
          -  Pleural effusion or ascites that causes respiratory compromise.&#xD;
&#xD;
          -  Any condition which, in the investigator's opinion, makes the subject unsuitable for&#xD;
             trial participation.&#xD;
&#xD;
          -  Known or suspected allergy or hypersensitivity to any of the study drugs, study drug&#xD;
             classes, or excipients of the formulations given during the course of this trial.&#xD;
&#xD;
          -  Persistent proteinuria ≥ Grade 3&#xD;
&#xD;
          -  History of organ allograft&#xD;
&#xD;
          -  Participants requiring warfarin or equivalent vitamin K antagonists (e.g.&#xD;
             phenprocoumon)&#xD;
&#xD;
          -  Participants with a condition requiring a strong CYP3A4 inhibitors or strong CYP3A4&#xD;
             inducers.&#xD;
&#xD;
          -  Unresolved toxicity higher than CTCAE grade 1 attributed to any prior therapy or&#xD;
             procedure, excluding alopecia.&#xD;
&#xD;
          -  Any hemorrhage or bleeding event ≥ NCI CTCAE Grade 3 within 4 weeks prior to start of&#xD;
             study medication.&#xD;
&#xD;
          -  Substance abuse, medical, psychological or social conditions that may interfere with&#xD;
             the patient's participation in the study or evaluation of the study results.&#xD;
&#xD;
          -  Participants with an arterial thrombotic or thromboembolic event within 6 months of&#xD;
             informed consent.&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV) infection or current chronic or&#xD;
             active hepatitis B or C infection.&#xD;
&#xD;
          -  Child-Pugh B cirrhosis (or worse) or a history of hepatic encephalopathy&#xD;
&#xD;
          -  History of stroke or intracranial hemorrhage within 6 months prior to enrollment.&#xD;
&#xD;
          -  Major surgery or a wound that has not fully healed within 4 weeks of enrollment.&#xD;
&#xD;
          -  Participants requiring concurrent anti-cancer therapy other than study treatment.&#xD;
&#xD;
          -  Participants requiring hormonal therapy during the study or within 2 weeks of first&#xD;
             study enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dae W Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 15, 2018</study_first_submitted>
  <study_first_submitted_qc>October 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2018</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colon cancer</keyword>
  <keyword>colorectal</keyword>
  <keyword>MMR</keyword>
  <keyword>Mismatch Repair</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

